Quantitative short echo time 1H MRSI of the peripheral edematous region of human brain tumors in the differentiation between glioblastoma, metastasis, and meningioma
J.P. Wijnen PhD
Department of Radiology, Radboud University Medical Centre Nijmegen, Nijmegen, The Netherlands
Search for more papers by this authorA.J.S. Idema MD
Department of Radiology, Radboud University Medical Centre Nijmegen, Nijmegen, The Netherlands
Department of Neurosurgery, Radboud University Medical Centre Nijmegen, Nijmegen, The Netherlands
Search for more papers by this authorM. Stawicki MSc
Department of Radiology, Radboud University Medical Centre Nijmegen, Nijmegen, The Netherlands
Search for more papers by this authorM.W. Lagemaat MSc
Department of Radiology, Radboud University Medical Centre Nijmegen, Nijmegen, The Netherlands
Search for more papers by this authorP. Wesseling PhD
Department of Pathology, Radboud University Medical Centre Nijmegen, Nijmegen, The Netherlands
Search for more papers by this authorA.J. Wright PhD
Department of Radiology, Radboud University Medical Centre Nijmegen, Nijmegen, The Netherlands
Search for more papers by this authorT.W.J. Scheenen PhD
Department of Radiology, Radboud University Medical Centre Nijmegen, Nijmegen, The Netherlands
Search for more papers by this authorCorresponding Author
A. Heerschap PhD
Department of Radiology, Radboud University Medical Centre Nijmegen, Nijmegen, The Netherlands
Department of Radiology (667), Radboud University Nijmegen Medical Center, Geertgroote plein 10, P.O. Box 9101, 6500 HB Nijmegen, The NetherlandsSearch for more papers by this authorJ.P. Wijnen PhD
Department of Radiology, Radboud University Medical Centre Nijmegen, Nijmegen, The Netherlands
Search for more papers by this authorA.J.S. Idema MD
Department of Radiology, Radboud University Medical Centre Nijmegen, Nijmegen, The Netherlands
Department of Neurosurgery, Radboud University Medical Centre Nijmegen, Nijmegen, The Netherlands
Search for more papers by this authorM. Stawicki MSc
Department of Radiology, Radboud University Medical Centre Nijmegen, Nijmegen, The Netherlands
Search for more papers by this authorM.W. Lagemaat MSc
Department of Radiology, Radboud University Medical Centre Nijmegen, Nijmegen, The Netherlands
Search for more papers by this authorP. Wesseling PhD
Department of Pathology, Radboud University Medical Centre Nijmegen, Nijmegen, The Netherlands
Search for more papers by this authorA.J. Wright PhD
Department of Radiology, Radboud University Medical Centre Nijmegen, Nijmegen, The Netherlands
Search for more papers by this authorT.W.J. Scheenen PhD
Department of Radiology, Radboud University Medical Centre Nijmegen, Nijmegen, The Netherlands
Search for more papers by this authorCorresponding Author
A. Heerschap PhD
Department of Radiology, Radboud University Medical Centre Nijmegen, Nijmegen, The Netherlands
Department of Radiology (667), Radboud University Nijmegen Medical Center, Geertgroote plein 10, P.O. Box 9101, 6500 HB Nijmegen, The NetherlandsSearch for more papers by this authorAbstract
Purpose:
To assess metabolite levels in peritumoral edematous (PO) and surrounding apparently normal (SAN) brain regions of glioblastoma, metastasis, and meningioma in humans with 1H-MRSI to find biomarkers that can discriminate between tumors and characterize infiltrative tumor growth.
Materials and Methods:
Magnetic resonance (MR) spectra (semi-LASER MRSI, 30 msec echo time, 3T) were selected from regions of interest (ROIs) under MRI guidance, and after quality control of MR spectra. Statistical testing between patient groups was performed for mean metabolite ratios of an entire ROI and for the highest value within that ROI.
Results:
The highest ratios of the level of choline compounds and the sum of myo-inositol and glycine over N-acetylaspartate and creatine compounds were significantly increased in PO regions of glioblastoma versus that of metastasis and meningioma. In the SAN region of glioblastoma some of these ratios were increased. Differences were less prominent for metabolite levels averaged over entire ROIs.
Conclusion:
Specific metabolite ratios in PO and SAN regions can be used to discriminate glioblastoma from metastasis and meningioma. An analysis of these ratios averaged over entire ROIs and those with most abnormal values indicates that infiltrative tumor growth in glioblastoma is inhomogeneous and extends into the SAN region. J. Magn. Reson. Imaging 2012;36:1072–1082. © 2012 Wiley Periodicals, Inc.
REFERENCES
- 1 CBTRUS. Statistical report: primary brain tumors in the United States, 2002–2004. Published by the Central Brain Tumor Registry of the United States; 2008.
- 2 Kaal EC, Niel CG, Vecht CJ. Therapeutic management of brain metastasis. Lancet Neurol 2005; 4: 289–298.
- 3 Buckner JC. Factors influencing survival in high-grade gliomas. Semin Oncol 2003; 30( 6 Suppl 19 ): 10–14.
- 4
Hall WA.
The safety and efficacy of stereotactic biopsy for intracranial lesions.
Cancer
1998;
82:
1749–1755.
10.1002/(SICI)1097-0142(19980501)82:9<1756::AID-CNCR23>3.0.CO;2-2 CAS PubMed Web of Science® Google Scholar
- 5 Howe FA, Barton SJ, Cudlip SA, et al. Metabolic profiles of human brain tumors using quantitative in vivo 1H magnetic resonance spectroscopy. Magn Reson Med 2003; 49: 223–232.
- 6 Li X, Lu Y, Pirzkall A, McKnight T, Nelson SJ. Analysis of the spatial characteristics of metabolic abnormalities in newly diagnosed glioma patients. J Magn Reson Imaging 2002; 16: 229–237.
- 7 Tate AR, Underwood J, Acosta DM, et al. Development of a decision support system for diagnosis and grading of brain tumours using in vivo magnetic resonance single voxel spectra. NMR Biomed 2006; 19: 411–434.
- 8 Nelson SJ. Multivoxel magnetic resonance spectroscopy of brain tumors. Mol Cancer Ther 2003; 2: 497–507.
- 9 Preul MC, Caramanos Z, Collins DL, et al. Accurate, noninvasive diagnosis of human brain tumors by using proton magnetic resonance spectroscopy. Nat Med 1996; 2: 323–325.
- 10 Ganslandt O, Stadlbauer A, Fahlbusch R, et al. Proton magnetic resonance spectroscopic imaging integrated into image-guided surgery: correlation to standard magnetic resonance imaging and tumor cell density. Neurosurgery 2005; 56(2 Suppl): 291–298; discussion 291–298.
- 11 Opstad KS, Griffiths JR, Bell BA, Howe FA. Apparent T(2) relaxation times of lipid and macromolecules: a study of high-grade tumor spectra. J Magn Reson Imaging 2008; 27: 178–184.
- 12 Opstad KS, Murphy MM, Wilkins PR, Bell BA, Griffiths JR, Howe FA. Differentiation of metastases from high-grade gliomas using short echo time 1H spectroscopy. J Magn Reson Imaging 2004; 20: 187–192.
- 13 Giese A, Bjerkvig R, Berens ME, Westphal M. Cost of migration: invasion of malignant gliomas and implications for treatment. J Clin Oncol 2003; 21: 1624–1636.
- 14 Claes A, Idema AJ, Wesseling P. Diffuse glioma growth: a guerilla war. Acta Neuropathol 2007; 114: 443–458.
- 15 McKnight TR, von dem Bussche MH, Vigneron DB, et al. Histopathological validation of a three-dimensional magnetic resonance spectroscopy index as a predictor of tumor presence. J Neurosurg 2002; 97: 794–802.
- 16 Pirzkall A, Nelson SJ, McKnight TR, et al. Metabolic imaging of low-grade gliomas with three-dimensional magnetic resonance spectroscopy. Int J Radiat Oncol Biol Phys 2002; 53: 1254–1264.
- 17 Stadlbauer A, Moser E, Gruber S, et al. Improved delineation of brain tumors: an automated method for segmentation based on pathologic changes of 1H-MRSI metabolites in gliomas. Neuroimage 2004; 23: 454–461.
- 18 McGirt MJ, Chaichana KL, Attenello FJ, et al. Extent of surgical resection is independently associated with survival in patients with hemispheric infiltrating low-grade gliomas. Neurosurgery 2008; 63: 700–707; author reply 707–708.
- 19 Fan G, Sun B, Wu Z, Guo Q, Guo Y. In vivo single-voxel proton MR spectroscopy in the differentiation of high-grade gliomas and solitary metastases. Clin Radiol 2004; 59: 77–85.
- 20 Ricci R, Bacci A, Tugnoli V, et al. Metabolic findings on 3T 1H-MR spectroscopy in peritumoral brain edema. AJNR Am J Neuroradiol 2007; 28: 1287–1291.
- 21 Chiang IC, Kuo YT, Lu CY, et al. Distinction between high-grade gliomas and solitary metastases using peritumoral 3-T magnetic resonance spectroscopy, diffusion, and perfusion imagings. Neuroradiology 2004; 46: 619–627.
- 22 Law M, Cha S, Knopp EA, Johnson G, Arnett J, Litt AW. High-grade gliomas and solitary metastases: differentiation by using perfusion and proton spectroscopic MR imaging. Radiology 2002; 222: 715–721.
- 23 Wijnen J, van Asten J, Klomp D, et al. Short echo time 1H MRSI of the human brain at 3T with adiabatic slice-selective refocusing pulses; reproducibility and variance in a dual centre setting. J Magn Reson Imaging 2010; 31: 61–70.
- 24 Scheenen TW, Klomp DW, Wijnen JP, Heerschap A. Short echo time 1H-MRSI of the human brain at 3T with minimal chemical shift displacement errors using adiabatic refocusing pulses. Magn Reson Med 2008; 59: 1–6.
- 25 Bottomley PA. Spatial localization in NMR spectroscopy in vivo. Ann N Y Acad Sci 1987; 508: 333–348.
- 26 Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med 1993; 30: 672–679.
- 27 Govindaraju V, Young K, Maudsley AA. Proton NMR chemical shifts and coupling constants for brain metabolites. NMR Biomed 2000; 13: 129–153.
- 28 Pfeuffer J, Tkac I, Provencher SW, Gruetter R. Toward an in vivo neurochemical profile: quantification of 18 metabolites in short-echo-time (1)H NMR spectra of the rat brain. J Magn Reson 1999; 141: 104–120.
- 29 Wright AJ, Arus C, Wijnen JP, et al. Automated quality control protocol for MR spectra of brain tumors. Magn Reson Med 2008; 59: 1274–1281.
- 30 Perez-Ruiz A, Julia-Sape M, Mercadal G, Olier I, Majos C, Arus C. The INTERPRET Decision-Support System version 3.0 for evaluation of Magnetic Resonance Spectroscopy data from human brain tumours and other abnormal brain masses. BMC Bioinformatics 2010; 11: 581.
- 31 Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983; 148: 839–843.
- 32 Chang L, McBride D, Miller BL, et al. Localized in vivo 1H magnetic resonance spectroscopy and in vitro analyses of heterogeneous brain tumors. J Neuroimaging 1995; 5: 157–163.
- 33 Usenius JP, Vainio P, Hernesniemi J, Kauppinen RA. Choline-containing compounds in human astrocytomas studied by 1H NMR spectroscopy in vivo and in vitro. J Neurochem 1994; 63: 1538–1543.
- 34 Pouwels PJ, Frahm J. Regional metabolite concentrations in human brain as determined by quantitative localized proton MRS. Magn Reson Med 1998; 39: 53–60.
- 35 Andersen C. In vivo estimation of water content in cerebral white matter of brain tumour patients and normal individuals: towards a quantitative brain oedema definition. Acta Neurochir 1997; 139: 249–255; discussion 255–246.
- 36 Andersen C, Astrup J, Gyldensted C. Quantitative MR analysis of glucocorticoid effects on peritumoral edema associated with intracranial meningiomas and metastases. J Comput Assist Tomogr 1994; 18: 509–518.
- 37 Seeger U, Klose U, Mader I, Grodd W, Nagele T. Parameterized evaluation of macromolecules and lipids in proton MR spectroscopy of brain diseases. Magn Reson Med 2003; 49: 19–28.
- 38 Lu S, Ahn D, Johnson G, Law M, Zagzag D, Grossman RI. Diffusion-tensor MR imaging of intracranial neoplasia and associated peritumoral edema: introduction of the tumor infiltration index. Radiology 2004; 232: 221–228.
- 39 Pavlisa G, Rados M, Pavic L, Potocki K, Mayer D. The differences of water diffusion between brain tissue infiltrated by tumor and peritumoral vasogenic edema. Clin Imaging 2009; 33: 96–101.
- 40 Kinoshita M, Goto T, Okita Y, et al. Diffusion tensor-based tumor infiltration index cannot discriminate vasogenic edema from tumor-infiltrated edema. J Neurooncol 2010; 96: 409–415.
- 41 Herminghaus S, Pilatus U, Moller-Hartmann W, et al. Increased choline levels coincide with enhanced proliferative activity of human neuroepithelial brain tumors. NMR Biomed 2002; 15: 385–392.
- 42 Nelson SJ, McKnight TR, Henry RG. Characterization of untreated gliomas by magnetic resonance spectroscopic imaging. Neuroimaging Clin N Am 2002; 12: 599–613.
- 43 Pirzkall A, McKnight TR, Graves EE, et al. MR-spectroscopy guided target delineation for high-grade gliomas. Int J Radiat Oncol Biol Phys 2001; 50: 915–928.
- 44 Thurston JH, Sherman WR, Hauhart RE, Kloepper RF. Myo-inositol: a newly identified nonnitrogenous osmoregulatory molecule in mammalian brain. Pediatr Res 1989; 26: 482–485.
- 45 Hattingen E, Raab P, Franz K, Zanella FE, Lanfermann H, Pilatus U. Myo-inositol: a marker of reactive astrogliosis in glial tumors? NMR Biomed 2008; 21: 233–241.
- 46 Castillo M, Smith JK, Kwock L. Correlation of myo-inositol levels and grading of cerebral astrocytomas. AJNR Am J Neuroradiol 2000; 21: 1645–1649.
- 47 Galanaud D, Chinot O, Nicoli F, et al. Use of proton magnetic resonance spectroscopy of the brain to differentiate gliomatosis cerebri from low-grade glioma. J Neurosurg 2003; 98: 269–276.
- 48 Kallenberg K, Bock HC, Helms G, et al. Untreated glioblastoma multiforme: increased myo-inositol and glutamine levels in the contralateral cerebral hemisphere at proton MR spectroscopy. Radiology 2009; 253: 805–812.
- 49 Gambarota G, Mekle R, Xin L, et al. In vivo measurement of glycine with short echo-time 1H MRS in human brain at 7 T. Magn Reson Mater Phys 2009; 22: 1–4.
- 50 Carpinelli G, Carapella CM, Palombi L, Raus L, Caroli F, Podo F. Differentiation of glioblastoma multiforme from astrocytomas by in vitro 1H MRS analysis of human brain tumors. Anticancer Res 1996; 16: 1559–1563.
- 51 Hattingen E, Lanfermann H, Quick J, Franz K, Zanella FE, Pilatus U. 1H MR spectroscopic imaging with short and long echo time to discriminate glycine in glial tumours. Magn Reson Mater Phys 2009; 22: 33–41.
- 52 Majos C, Alonso J, Aguilera C, et al. Proton magnetic resonance spectroscopy ((1)H MRS) of human brain tumours: assessment of differences between tumour types and its applicability in brain tumour categorization. Eur Radiol 2003; 13: 582–591.
- 53 Righi V, Andronesi OC, Mintzopoulos D, Black PM, Tzika AA. High-resolution magic angle spinning magnetic resonance spectroscopy detects glycine as a biomarker in brain tumors. Int J Oncol 2011; 36: 301–306.
- 54 Galanaud D, Nicoli F, Chinot O, et al. Noninvasive diagnostic assessment of brain tumors using combined in vivo MR imaging and spectroscopy. Magn Reson Med 2006; 55: 1236–1245.
- 55 De Edelenyi FS, Rubin C, Esteve F, et al. A new approach for analyzing proton magnetic resonance spectroscopic images of brain tumors: nosologic images. Nat Med 2000; 6: 1287–1289.
- 56 Devos A, Lukas L, Suykens JA, et al. Classification of brain tumours using short echo time 1H MR spectra. J Magn Reson 2004; 170: 164–175.
- 57 Moller-Hartmann W, Herminghaus S, Krings T, et al. Clinical application of proton magnetic resonance spectroscopy in the diagnosis of intracranial mass lesions. Neuroradiology 2002; 44: 371–381.
- 58 Garcia-Gomez JM, Luts J, Julia-Sape M, et al. Multiproject-multicenter evaluation of automatic brain tumor classification by magnetic resonance spectroscopy. Magn Reson Mater Phys 2009; 22: 5–18.
- 59 Chawla S, Zhang Y, Wang S, et al. Proton magnetic resonance spectroscopy in differentiating glioblastomas from primary cerebral lymphomas and brain metastases. J Comput Assist Tomogr 2010; 34: 836–841.
- 60 Stadlbauer A, Gruber S, Nimsky C, et al. Preoperative grading of gliomas by using metabolite quantification with high-spatial-resolution proton MR spectroscopic imaging. Radiology 2006; 238: 958–969.
- 61 Cha S. Neuroimaging in neuro-oncology. Neurotherapeutics 2009; 6: 465–477.
- 62 Tagle P, Villanueva P, Torrealba G, Huete I. Intracranial metastasis or meningioma? An uncommon clinical diagnostic dilemma. Surg Neurol 2002; 58: 241–245.
- 63 Zhang M, Olsson Y. Hematogenous metastases of the human brain—characteristics of peritumoral brain changes: a review. J Neurooncol 1997; 35: 81–89.
